New combo therapy aims to boost lung cancer fight
NCT ID NCT01345851
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial is testing a new way to give radiation therapy for people with stage II-III non-small cell lung cancer that cannot be removed with surgery. Instead of standard daily radiation for many weeks, patients receive a shorter, higher-dose course (hypofractionated radiation) along with chemotherapy drugs carboplatin and paclitaxel. The main goal is to find the highest safe radiation dose, while also checking if this approach helps control the tumor and improves survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- carboplatin and paclitaxel (chemotherapy drugs) plus hypofractionated radiation therapy
- What this could lead to
- If successful, this approach could offer a more effective and shorter treatment option for people with inoperable lung cancer, potentially improving local tumor control and survival.
- What could go wrong
- This is a small, early-phase trial (29 participants) focused on finding the safest radiation dose, not yet proving effectiveness. Side effects from high-dose radiation and chemotherapy can be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA OF THE LUNG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Personalized cancer care: genetic analysis may unlock targeted treatments for advanced lung cancer
- Can an immunotherapy cocktail shrink inoperable lung tumors?
- Blood test could reveal how lung cancer evolves during treatment
- New drug IDP-001 takes on advanced cancers in early trial
- Step counts may predict trouble during lung cancer therapy
- Experimental immune cell therapy targets Hard-to-Treat cancers